arrow
M

Maciej Jabłkowski

Medical University Lodz
H指数:17
被引数:1,973

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Eight-year efficacy and safety of tenofovir alafenamide for treatment of chronic hepatitis B virus infection: Final results from two randomised phase 3 trials
2024-09-272
OAAI
Atherosclerotic cardiovascular disease risk profile of patients with chronic hepatitis B treated with tenofovir alafenamide or tenofovir disoproxil fumarate for 96 weeks

用替诺福韦艾拉酚胺或富马酸替诺福韦酯治疗96周的慢性乙型肝炎患者的动脉粥样硬化性心血管疾病风险概况

2023-10-315
OA
Long-Term Treatment With Tenofovir Alafenamide for Chronic Hepatitis B Results in High Rates of Viral Suppression and Favorable Renal and Bone Safety

替诺福韦Alafenamide长期治疗慢性乙型肝炎导致高病毒抑制率和良好的肾脏和骨骼安全性

2023-08-0914
OAAI
Bone and renal safety are improved in chronic HBV patients switched to tenofovir alafenamide (TAF) after either 2 or 3 years of prior tenofovir disoproxil fumarate (TDF) treatment
2019-04-011
PREAI
Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)/TDF in lamivudine resistant hepatitis B: A 5-year randomised study
2017-01-0144
PREAI
Real-world effectiveness and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C: AMBER study
2016-09-0994
OAAI
Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin
2015-02-0120
PREAI